• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纤维连接蛋白的血管生成相关额外结构域 B 的选择性剪接调节了第 8 型重复 3 结构域 B-C 环的可及性。

Alternative splicing of the angiogenesis associated extra-domain B of fibronectin regulates the accessibility of the B-C loop of the type III repeat 8.

机构信息

Laboratory of Recombinant Therapeutic Proteins, CBA - Advanced Biotechnology Centre, Genoa, Italy.

出版信息

PLoS One. 2010 Feb 10;5(2):e9145. doi: 10.1371/journal.pone.0009145.

DOI:10.1371/journal.pone.0009145
PMID:20161770
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2818841/
Abstract

BACKGROUND

Fibronectin (FN) is a multi-domain molecule involved in many cellular processes, including tissue repair, embryogenesis, blood clotting, and cell migration/adhesion. The biological activities of FN are mediated by exposed loops located mainly at the interdomain interfaces that interact with various molecules such as, but not only, integrins. Different FN isoforms arise from the alternative splicing of the pre-mRNA. In malignancies, the splicing pattern of FN pre-mRNA is altered; in particular, the FN isoform containing the extra-domain B (ED-B), a complete FN type III repeat constituted by 91 residues, is undetectable in normal adult tissues, but exhibits a much greater expression in fetal and tumor tissues, and is accumulated around neovasculature during angiogenic processes, thus making ED-B one of the best markers and targets of angiogenesis. The functions of ED-B are still unclear; however, it has been postulated that the insertion of an extra-domain such as ED-B modifies the domain-domain interface and may unmask loops that are otherwise cryptic, thus giving FN new potential activities.

METHODOLOGY

We used the mAb C6, which reacts with ED-B containing FN, but not with ED-B-free FN and various recombinant FN fragments containing mutations, to precisely localize the epitopes recognized by the mAb C6.

CONCLUSION

We formally demonstrated that the inclusion of the alternatively spliced angiogenesis-associated ED-B leads to the unmasking of the FNIII 8 B-C loop that is cryptic in FN molecules lacking ED-B. Thus, the mAb C6, in addition to providing a new reagent for angiogenesis targeting, represents a new tool for the study of the potential biological functions of the B-C loop of the repeat FNIII 8 that is unmasked during angiogenic processes.

摘要

背景

纤连蛋白(FN)是一种多功能分子,参与许多细胞过程,包括组织修复、胚胎发生、血液凝固和细胞迁移/黏附。FN 的生物学活性由主要位于域间界面的暴露环介导,这些环与各种分子相互作用,如整合素等。不同的 FN 同种型由前 mRNA 的选择性剪接产生。在恶性肿瘤中,FN 前 mRNA 的剪接模式发生改变;特别是,包含额外结构域 B(ED-B)的 FN 同种型,它是由 91 个残基组成的完整 FN 型 III 重复,在正常成人组织中无法检测到,但在胎儿和肿瘤组织中表达量更大,并在血管生成过程中积累在新血管周围,因此 ED-B 成为血管生成的最佳标志物和靶点之一。ED-B 的功能尚不清楚;然而,据推测,插入额外结构域(如 ED-B)会改变结构域-结构域界面,并可能揭示原本隐匿的环,从而为 FN 赋予新的潜在活性。

方法

我们使用与含有 ED-B 的 FN 反应、但与不含 ED-B 的 FN 以及含有突变的各种重组 FN 片段均不反应的 mAb C6,精确定位 mAb C6 识别的表位。

结论

我们正式证明,包含选择性剪接的血管生成相关 ED-B 会导致 FN 分子中隐匿的 FNIII 8 B-C 环暴露。因此,mAb C6 不仅为血管生成靶向提供了新的试剂,而且代表了研究血管生成过程中暴露的 FNIII 8 重复 B-C 环潜在生物学功能的新工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d67e/2818841/32222d183568/pone.0009145.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d67e/2818841/49589cd8e2f0/pone.0009145.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d67e/2818841/32222d183568/pone.0009145.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d67e/2818841/49589cd8e2f0/pone.0009145.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d67e/2818841/32222d183568/pone.0009145.g002.jpg

相似文献

1
Alternative splicing of the angiogenesis associated extra-domain B of fibronectin regulates the accessibility of the B-C loop of the type III repeat 8.纤维连接蛋白的血管生成相关额外结构域 B 的选择性剪接调节了第 8 型重复 3 结构域 B-C 环的可及性。
PLoS One. 2010 Feb 10;5(2):e9145. doi: 10.1371/journal.pone.0009145.
2
C6: A Monoclonal Antibody Specific for a Fibronectin Epitope Situated at the Interface between the Oncofoetal Extra-Domain B and the Repeat III8.C6:一种针对位于癌胚性外显子 B 与重复 III8 之间界面的纤连蛋白表位的单克隆抗体。
PLoS One. 2016 Feb 11;11(2):e0148103. doi: 10.1371/journal.pone.0148103. eCollection 2016.
3
NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis.人癌胚纤连蛋白ED-B结构域的核磁共振结构,血管生成的特异性标志物
Structure. 1999 Apr 15;7(4):381-90. doi: 10.1016/s0969-2126(99)80051-3.
4
The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence.
J Biol Chem. 1992 Dec 5;267(34):24689-92.
5
The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis.含有ED-B癌胚结构域的纤连蛋白异构体:血管生成的标志物。
Int J Cancer. 1994 Dec 1;59(5):612-8. doi: 10.1002/ijc.2910590507.
6
A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis-associated extra type III domain B.一种新的人类纤连蛋白隐蔽序列因插入血管生成相关的额外III型结构域B而暴露。
Int J Cancer. 2009 Aug 15;125(4):751-8. doi: 10.1002/ijc.24473.
7
Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain.对癌胚血管生成标志物纤连蛋白ED-B结构域具有全物种识别能力的噬菌体抗体。
Int J Cancer. 1996 Nov 4;68(3):397-405. doi: 10.1002/(SICI)1097-0215(19961104)68:3<397::AID-IJC20>3.0.CO;2-4.
8
Tissue stiffness regulates serine/arginine-rich protein-mediated splicing of the extra domain B-fibronectin isoform in tumors.组织硬度调节肿瘤中富含丝氨酸/精氨酸蛋白介导的额外结构域B纤连蛋白异构体的剪接。
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8314-9. doi: 10.1073/pnas.1505421112. Epub 2015 Jun 23.
9
Tc-Anti-ED-B fibronectin single-chain antibody fragment L19-His锝标记抗ED-B纤连蛋白单链抗体片段L19-组氨酸
10
Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.使用抗纤连蛋白额外结构域B的人重组抗体鉴别高级别和低级别星形细胞瘤。
Am J Pathol. 2002 Nov;161(5):1695-700. doi: 10.1016/S0002-9440(10)64446-X.

引用本文的文献

1
Exploring the mechanism of fibronectin extra domain B in the tumor microenvironment and implications for targeted immunotherapy and diagnostics (Review).探索纤连蛋白额外结构域B在肿瘤微环境中的作用机制及其对靶向免疫治疗和诊断的意义(综述)
Mol Med Rep. 2025 Jun;31(6). doi: 10.3892/mmr.2025.13525. Epub 2025 Apr 11.
2
Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma.纤连蛋白外显子 B 作为药物传递的替代靶点,以及用于恶性神经胶质瘤的癌症诊断和预后生物标志物。
Theranostics. 2021 Jan 1;11(2):941-957. doi: 10.7150/thno.44948. eCollection 2021.
3

本文引用的文献

1
A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis-associated extra type III domain B.一种新的人类纤连蛋白隐蔽序列因插入血管生成相关的额外III型结构域B而暴露。
Int J Cancer. 2009 Aug 15;125(4):751-8. doi: 10.1002/ijc.24473.
2
Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients.癌胚性含ED-B纤连蛋白异构体在血液肿瘤中的表达使针对ED-B的131I-L19SIP放射免疫疗法可用于霍奇金淋巴瘤患者。
Blood. 2009 Mar 5;113(10):2265-74. doi: 10.1182/blood-2008-06-160416. Epub 2009 Jan 8.
3
Alternatively spliced isoforms reveal a novel type of PTB domain in CCM2 protein.
剪接变异异构体揭示 CCM2 蛋白中新型的 PTB 结构域。
Sci Rep. 2019 Nov 1;9(1):15808. doi: 10.1038/s41598-019-52386-0.
4
Genetically Programmable Self-Regenerating Bacterial Hydrogels.基因可编程的自修复细菌水凝胶。
Adv Mater. 2019 Oct;31(40):e1901826. doi: 10.1002/adma.201901826. Epub 2019 Aug 12.
5
Targeting Fibronectin for Cancer Imaging and Therapy.靶向纤连蛋白用于癌症成像与治疗
J Mater Chem B. 2017 Jan 28;5(4):639-654. doi: 10.1039/C6TB02008A. Epub 2016 Dec 1.
6
Fibronectin Mechanobiology Regulates Tumorigenesis.纤连蛋白力学生物学调控肿瘤发生。
Cell Mol Bioeng. 2016;9:1-11. doi: 10.1007/s12195-015-0417-4. Epub 2015 Aug 15.
7
C6: A Monoclonal Antibody Specific for a Fibronectin Epitope Situated at the Interface between the Oncofoetal Extra-Domain B and the Repeat III8.C6:一种针对位于癌胚性外显子 B 与重复 III8 之间界面的纤连蛋白表位的单克隆抗体。
PLoS One. 2016 Feb 11;11(2):e0148103. doi: 10.1371/journal.pone.0148103. eCollection 2016.
8
The EIIIA domain from astrocyte-derived fibronectin mediates proliferation of oligodendrocyte progenitor cells following CNS demyelination.来自星形胶质细胞衍生纤连蛋白的EIIIA结构域介导中枢神经系统脱髓鞘后少突胶质细胞祖细胞的增殖。
Glia. 2015 Feb;63(2):242-56. doi: 10.1002/glia.22748. Epub 2014 Aug 25.
9
Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy.致癌性可变剪接开关:在癌症进展中的作用及治疗前景
Int J Cell Biol. 2013;2013:962038. doi: 10.1155/2013/962038. Epub 2013 Oct 27.
10
Extra-domain B in oncofetal fibronectin structurally promotes fibrillar head-to-tail dimerization of extracellular matrix protein.癌胚纤维连接蛋白外结构域 B 在结构上促进细胞外基质蛋白纤维状的头对头二聚化。
J Biol Chem. 2012 May 18;287(21):17578-17588. doi: 10.1074/jbc.M111.303131. Epub 2012 Mar 22.
Structural insights into fibronectin type III domain-mediated signaling.
纤连蛋白III型结构域介导信号传导的结构见解。
J Mol Biol. 2007 Mar 23;367(2):303-9. doi: 10.1016/j.jmb.2006.10.017. Epub 2006 Oct 11.
4
Tumour vascular targeting.肿瘤血管靶向
Nat Rev Cancer. 2005 Jun;5(6):436-46. doi: 10.1038/nrc1627.
5
Selective targeted delivery of TNFalpha to tumor blood vessels.肿瘤坏死因子α向肿瘤血管的选择性靶向递送。
Blood. 2003 Dec 15;102(13):4384-92. doi: 10.1182/blood-2003-04-1039. Epub 2003 Aug 21.
6
Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.使用抗纤连蛋白额外结构域B的人重组抗体鉴别高级别和低级别星形细胞瘤。
Am J Pathol. 2002 Nov;161(5):1695-700. doi: 10.1016/S0002-9440(10)64446-X.
7
Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin.肿瘤血管的选择性靶向:抗纤连蛋白ED-B结构域的抗体(L19)不同形式的比较
Int J Cancer. 2002 Nov 1;102(1):75-85. doi: 10.1002/ijc.10662.
8
Fibronectin at a glance.纤连蛋白一览。
J Cell Sci. 2002 Oct 15;115(Pt 20):3861-3. doi: 10.1242/jcs.00059.
9
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.通过将白细胞介素-2靶向递送至肿瘤血管细胞外基质来增强其抗肿瘤特性。
Blood. 2002 Mar 1;99(5):1659-65. doi: 10.1182/blood.v99.5.1659.
10
NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis.人癌胚纤连蛋白ED-B结构域的核磁共振结构,血管生成的特异性标志物
Structure. 1999 Apr 15;7(4):381-90. doi: 10.1016/s0969-2126(99)80051-3.